The PLATelet inhibition and patient Outcomes (PLATO) trial included patients with ST‐elevation and non‐ST‐elevation ACS, and showed that ticagrelor was superior to clopidogrel treatment in preventing CV mortality, myocardial infarction (MI), or stroke.9, 10 In the current biomarker substudy, we aimed to (a) evaluate the association between IL‐18 concentrations and CV outcomes and bleeding and (b) explore the IL‐18 concentrations during follow‐up, and (c) assess possible interactions with randomized treatment (ticagrelor or clopidogrel). This evidence concerns the gene IL18 and myocardial infarction.